Comparative Pharmacology
Head-to-head clinical analysis: CONSTULOSE versus GLYCOPREP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONSTULOSE versus GLYCOPREP.
CONSTULOSE vs GLYCOPREP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. In the colon, it is metabolized by bacteria to short-chain fatty acids, leading to an osmotic effect that draws water into the bowel, thereby softening stools and increasing bowel motility. In hepatic encephalopathy, lactulose acidifies the colonic environment, promoting the conversion of ammonia (NH3) to ammonium (NH4+), which is trapped and excreted in feces.
Glycopyrrolate is a competitive antagonist of acetylcholine at muscarinic receptors, thereby inhibiting the effects of parasympathetic nervous system activation. It does not cross the blood-brain barrier significantly, producing peripheral anticholinergic effects.
10-20 g (15-30 mL) orally once daily, increased to 30-45 g (45-60 mL) if needed; or 30-45 g (45-60 mL) orally every 6-8 hours for hepatic encephalopathy.
Adults: 10 units subcutaneously 30 minutes before first meal of the day, then 5 units after each subsequent meal. Total daily dose should not exceed 30 units.
None Documented
None Documented
Not applicable due to minimal systemic absorption; local action in colon. In cases of systemic absorption, half-life is not clinically relevant.
Terminal half-life 1.5-2 hours in adults; prolonged in renal impairment (up to 10-12 hours in anuria).
Primarily fecal (unchanged); minimal systemic absorption (<3%), thus negligible renal excretion.
Primarily renal (90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <10%.
Category C
Category C
Osmotic Laxative
Osmotic Laxative